387 related articles for article (PubMed ID: 29455579)
21. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
Citrome LL
J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
[TBL] [Abstract][Full Text] [Related]
22. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
23. Tardive Dyskinesia: Treatment Update.
Arya D; Khan T; Margolius AJ; Fernandez HH
Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
[TBL] [Abstract][Full Text] [Related]
24. Current treatment of tardive dyskinesia.
Margolius A; Fernandez HH
Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
[TBL] [Abstract][Full Text] [Related]
25. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
[TBL] [Abstract][Full Text] [Related]
26. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
Citrome L; Saklad SR
J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
[TBL] [Abstract][Full Text] [Related]
27. VMAT2 inhibitors for the treatment of tardive dyskinesia.
Scorr LM; Factor SA
J Neurol Sci; 2018 Jun; 389():43-47. PubMed ID: 29433808
[TBL] [Abstract][Full Text] [Related]
28. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
[TBL] [Abstract][Full Text] [Related]
29. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
30. Valbenazine (Ingrezza) for tardive dyskinesia.
Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
[No Abstract] [Full Text] [Related]
31. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
Dorfman BJ; Jimenez-Shahed J
Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
[No Abstract] [Full Text] [Related]
32. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
[TBL] [Abstract][Full Text] [Related]
33. VMAT2 Inhibitors in Neuropsychiatric Disorders.
Tarakad A; Jimenez-Shahed J
CNS Drugs; 2018 Dec; 32(12):1131-1144. PubMed ID: 30306450
[TBL] [Abstract][Full Text] [Related]
34. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
Müller T
Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
[TBL] [Abstract][Full Text] [Related]
35. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
[No Abstract] [Full Text] [Related]
36. Valbenazine-induced parkinsonism.
Akbar U; Kim DS; Friedman JH
Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
[No Abstract] [Full Text] [Related]
37. Treatment of Tardive Dyskinesia.
Bashir HH; Jankovic J
Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
39. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
40. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
